https://fore.bio/ 2026-04-28T16:00:11+00:00 https://fore.bio/news/ 2026-05-12T12:01:17+00:00 https://fore.bio/events/ 2025-10-12T21:49:44+00:00 https://fore.bio/company/investors/ 2025-05-05T17:27:57+00:00 https://fore.bio/expanded-access/ 2024-06-03T19:27:48+00:00 https://fore.bio/science/publications/ 2022-04-05T18:16:06+00:00 https://fore.bio/search/ 2021-09-27T20:41:17+00:00 https://fore.bio/internet-policy/ 2026-04-20T17:43:58+00:00 https://fore.bio/legal-statement/ 2022-05-12T21:10:10+00:00 https://fore.bio/company/governance/ 2021-11-11T19:35:42+00:00 https://fore.bio/company/careers/ 2021-11-11T19:34:10+00:00 https://fore.bio/company/leadership/ 2026-05-05T19:58:10+00:00 https://fore.bio/company/people/ 2025-05-05T16:13:45+00:00 https://fore.bio/company/about-us/ 2025-05-05T16:10:11+00:00 https://fore.bio/patients/science-explained/ 2025-03-11T20:30:14+00:00 https://fore.bio/patients/clinical-trials/ 2025-05-05T16:07:02+00:00 https://fore.bio/science/fore-8394-program/ 2025-05-05T16:05:45+00:00 https://fore.bio/company/ 2022-04-29T19:35:44+00:00 https://fore.bio/patients/ 2021-09-02T17:18:02+00:00 https://fore.bio/science/ 2021-09-02T17:17:59+00:00 https://fore.bio/pipeline/ 2025-05-05T16:03:12+00:00 https://fore.bio/contact/ 2026-05-05T20:06:43+00:00 https://fore.bio/partnerships/ 2026-05-05T20:04:38+00:00 https://fore.bio/fore-biotherapeutics-to-participate-in-upcoming-investor-conferences-4/ 2026-05-12T12:01:17+00:00 https://fore.bio/publication/clinical-activity-and-safety-of-novel-braf-inhibitor-plixorafenib-fore8394-in-braf-v600-mutated-advanced-colorectal-cancers-crc-r1/ 2026-04-20T12:54:29+00:00 https://fore.bio/publication/forte-a-phase-2-master-protocol-assessing-plixorafenib-for-braf-altered-cancers-2/ 2026-04-20T12:54:17+00:00 https://fore.bio/fore-biotherapeutics-receives-breakthrough-therapy-designation-for-plixorafenib/ 2026-04-02T13:26:48+00:00 https://fore.bio/events/the-biocentury-show-inside-precision-oncologys-next-chapter-with-bill-hinshaw/ 2025-12-08T15:19:35+00:00 https://fore.bio/publication/plixorafenib_treatment_sustained_tumor_regression_preclinical_models/ 2025-11-10T21:30:40+00:00 https://fore.bio/fore-biotherapeutics-to-participate-in-upcoming-investor-conferences-3/ 2025-11-04T13:16:08+00:00 https://fore.bio/fore-biotherapeutics-to-host-virtual-key-opinion-leader-roundtable-discussion-on-plixorafenibs-potential-to-disrupt-the-braf-market-to-benefit-patients/ 2025-10-13T12:06:37+00:00 https://fore.bio/events/kol-roundtable-discussion-on-plixorafenib/ 2025-10-15T17:11:44+00:00 https://fore.bio/fore-biotherapeutics-announces-positive-outcome-from-a-planned-interim-efficacy-analysis-for-the-forte-basket-study-evaluating-plixorafenib-as-a-monotherapy-for-recurrent-or-progressive-braf-v600-prim/ 2025-09-24T12:02:07+00:00 https://fore.bio/publication/clinical_activity_safety_brafi_plixo_in_atc_harborinng_braf_alterations/ 2025-11-10T15:33:31+00:00 https://fore.bio/publication/effect-of-food-cobicistat-administration-on-the-pharmacokinetics-safety-of-plixorafenib-in-healthy-participants/ 2025-09-16T09:57:22+00:00 https://fore.bio/fore_biotherapeutics_presents_plixorafenib_data_ata_2025/ 2025-09-12T21:09:41+00:00 https://fore.bio/people/rajeev_dadoo/ 2025-08-27T13:13:08+00:00 https://fore.bio/fore_biotherapeutics_to_participate_upcoming_investor_conferences_2025/ 2025-08-27T12:58:04+00:00 https://fore.bio/publication/forte_phase_2_master_protocol_trial-_in-progress/ 2025-05-31T20:12:35+00:00 https://fore.bio/fore_biotherapeutics_to_participate_jeffries_2025/ 2025-05-27T12:50:05+00:00 https://fore.bio/fore_biotherapeutics_raises_38_million_series_d-2_financing/ 2025-05-22T12:02:45+00:00 https://fore.bio/fore_biotherapeutics_to_present_plixorafenib_abstract_at_asco_2025/ 2025-04-30T14:18:49+00:00 https://fore.bio/publication/circulating_tumor_dna_analysis_plixorafenib_study/ 2025-04-25T17:22:34+00:00 https://fore.bio/publication/forte-a-phase-2-master-protocol-assessing-plixorafenib-for-braf-altered-cancers/ 2025-04-25T17:22:02+00:00 https://fore.bio/fore_biotherapeutics_presents_new_plixorafenivb_results_at_aacr_2025/ 2025-04-25T17:06:37+00:00 https://fore.bio/fore_biotherapeutics_present_at_aacr_2025/ 2025-03-31T16:22:58+00:00 https://fore.bio/fore_biotherapeutics_participate_in_the_raymond_james_biotech_symposium/ 2025-02-13T14:27:53+00:00 https://fore.bio/fore_biotherapeutics_highlights_recent_pipeline_achievements_2025/ 2025-01-09T22:32:08+00:00 https://fore.bio/fore_biotherapeutics_to_at-the-43rd-annual-j-p-morgan-healthcare-conference/ 2024-12-19T15:49:43+00:00 https://fore.bio/fore_biotherapeutics_to_participate_in_wells_fargo_virtual_symposium/ 2024-12-05T14:28:42+00:00 https://fore.bio/fore_biotherapeutics_to_participate_in_upcoming_investor_conferences/ 2024-12-18T21:14:41+00:00 https://fore.bio/publication/activity-of-braf-inhibitor-plixorafenib-in-advanced-ovarian-cancer-harboring-braf-v600-mutation/ 2025-05-06T19:18:09+00:00 https://fore.bio/publication/safety-and-efficacy-of-plixorafenib-in-braf-altered-pcnsts/ 2024-10-17T13:37:36+00:00 https://fore.bio/fore_biotherapeutics_presents_at_rbc-2024/ 2024-10-08T12:16:37+00:00 https://fore.bio/fore_biotherapeutics_presents_at_ubs_2024/ 2024-09-26T11:59:03+00:00 https://fore.bio/fore-biotherapeutics-to-participate-in-upcoming-investor-conferences-2/ 2024-12-18T21:15:29+00:00 https://fore.bio/people/michaelbyrnes/ 2025-06-25T21:09:44+00:00 https://fore.bio/fore-biotherapeutics-names-michael-byrnes-as-cfo/ 2024-12-18T21:17:28+00:00 https://fore.bio/people/paymandarouian/ 2025-06-25T21:11:51+00:00 https://fore.bio/present-at-the-2024-goldman-sachs-conference/ 2024-12-18T21:22:08+00:00 https://fore.bio/present-at-the-2024-rbc-capital-markets-global-healthcare-conference/ 2024-05-10T15:17:02+00:00 https://fore.bio/publication/paradox-breaker-braf-inhibitor-plixorafenib-fore8394-synergizes-with-meki/ 2024-04-17T17:29:42+00:00 https://fore.bio/publication/efficacy-of-braf-inhibitor-in-recurrent-pcnst/ 2024-04-17T17:26:58+00:00 https://fore.bio/publication/safety-efficacy-of-braf-inhibitor-fore8394-patients-w-advanced-solid-cns-tumors/ 2024-04-17T17:23:42+00:00 https://fore.bio/publication/dose-optimization-of-novel-braf-inhibitor-fore8394/ 2024-04-26T16:57:27+00:00 https://fore.bio/fore-biotherapeutics-presenting-at-stifel-2024-virtual-targeted-oncology-forum/ 2024-04-11T16:37:58+00:00 https://fore.bio/fore-biotherapeutics-announced-new-nonclinical-data-highlighting-the-differentiation-of-plixorafenib-in-combination-with-mek-inhibition-at-aacr24/ 2024-04-09T14:35:31+00:00 https://fore.bio/people/williamhinshaw/ 2025-06-25T21:10:58+00:00 https://fore.bio/fore-biotherapeutics-names-william-r-hinshaw-as-chief-executive-officer/ 2024-12-18T21:30:48+00:00 https://fore.bio/fore-biotherapeutics-to-participate-in-upcoming-investor-conferences/ 2024-12-18T21:29:37+00:00 https://fore.bio/fore-biotherapeutics-to-present-at-the-2023-rbc-capital-markets-private-company-conference/ 2023-12-07T20:40:46+00:00 https://fore.bio/fore-biotherapeutics-announces-oral-presentation-at-sno-2023-reporting-updated-phase-1-2a-results-for-plixorafenib-in-braf-v600-advanced-solid-tumors-including-novel-data-for-patients-with-braf-v600/ 2023-11-18T07:38:14+00:00 https://fore.bio/fore-biotherapeutics-announces-oral-presentation-of-phase-1-2a-plixorafenib-data-at-the-society-for-neuro-oncology-2023-annual-meeting/ 2023-11-11T16:54:29+00:00 https://fore.bio/fore-biotherapeutics-to-present-plixorafenib-nonclinical-data-highlighting-potential-differentiation-at-the-2023-aacr-nci-eortc-international-conference/ 2023-10-14T18:23:44+00:00 https://fore.bio/fore-biotherapeutics-announces-75m-in-series-d-financing-and-ceo-transition/ 2023-08-23T13:12:06+00:00 https://fore.bio/fore-biotherapeutics-to-present-promising-new-data-from-phase-1-2a-trial-evaluating-plixorafenib-fore8394-in-patients-with-braf-altered-advanced-solid-and-central-nervous-system-tumors-at-asco-2023/ 2023-05-28T08:25:43+00:00 https://fore.bio/fore-biotherapeutics-announces-two-abstracts-accepted-for-presentation-at-the-2023-american-society-of-clinical-oncology-asco-annual-meeting/ 2023-04-27T12:54:58+00:00 https://fore.bio/fore-biotherapeutics-receives-fda-orphan-drug-designation-for-fore8394-for-the-treatment-of-primary-brain-and-cns-malignancies/ 2023-03-20T12:16:58+00:00 https://fore.bio/fore-biotherapeutics-announces-first-patient-dosed-in-global-phase-2-trial-evaluating-fore8394-in-braf-mutated-solid-and-brain-tumors/ 2023-02-23T13:03:55+00:00 https://fore.bio/fore-biotherapeutics-announces-fast-track-designation-granted-by-fda-to-fore8394-for-the-treatment-of-cancers-harboring-braf-class-1-and-class-2-alterations/ 2022-09-28T17:51:39+00:00 https://fore.bio/publication/efficacy-of-braf-inhibitor-fore8394-in-braf-v600-patients/ 2022-09-13T17:07:05+00:00 https://fore.bio/fore-biotherapeutics-presents-positive-interim-data-from-phase-1-2a-trial-evaluating-fore8394-in-patients-with-advanced-tumors-with-activating-braf-alterations-at-esmo-2022/ 2022-09-12T12:23:49+00:00 https://fore.bio/people/jeff-sacher/ 2023-09-03T12:36:51+00:00 https://fore.bio/people/brian-schwartz/ 2025-03-18T18:59:23+00:00 https://fore.bio/people/david-solit/ 2021-11-10T19:08:35+00:00 https://fore.bio/people/filip-janku/ 2021-11-10T19:13:48+00:00 https://fore.bio/people/kim-blackwell/ 2026-05-05T22:30:01+00:00 https://fore.bio/people/meenu-chhabra-karson/ 2022-08-24T14:14:02+00:00 https://fore.bio/people/giovanni-mariggi/ 2023-09-07T05:15:42+00:00 https://fore.bio/people/michal-silverberg/ 2021-11-10T19:16:45+00:00 https://fore.bio/people/matthew-foy/ 2021-11-10T19:17:21+00:00 https://fore.bio/people/chandra-leo/ 2021-11-10T19:17:39+00:00 https://fore.bio/people/tomer-kariv/ 2021-11-10T19:19:31+00:00 https://fore.bio/people/erez-chimovits/ 2021-11-10T19:20:25+00:00 https://fore.bio/people/dieter-weinand/ 2022-04-13T13:52:21+00:00 https://fore.bio/people/stacie-shepherd/ 2025-06-25T21:09:00+00:00 https://fore.bio/people/jessica-rine/ 2021-11-10T19:26:19+00:00 https://fore.bio/people/steve-averbuch-md/ 2021-11-10T19:31:31+00:00 https://fore.bio/publication/duplicated-publication-34-2-2-2/ 2022-04-05T18:17:16+00:00 https://fore.bio/publication/aacr-virtual-annual-meeting-i-insights-gained-from-aacr-project-genie/ 2022-08-24T13:45:43+00:00 https://fore.bio/publication/duplicated-publication-34-2-5-3/ 2022-08-24T13:46:42+00:00 https://fore.bio/publication/duplicated-publication-34-2-2-3/ 2022-04-05T17:44:46+00:00 https://fore.bio/publication/duplicated-publication-34-6/ 2022-04-05T17:53:47+00:00 https://fore.bio/publication/duplicated-publication-34-5/ 2022-08-24T13:50:43+00:00 https://fore.bio/publication/duplicated-publication-34-2-5/ 2022-08-24T13:50:15+00:00 https://fore.bio/publication/duplicated-publication-34-2-4/ 2022-08-24T13:49:38+00:00 https://fore.bio/publication/duplicated-publication-34-2-3/ 2022-08-24T13:49:53+00:00 https://fore.bio/publication/duplicated-publication-34-4/ 2022-08-24T13:47:39+00:00 https://fore.bio/publication/duplicated-publication-34-6-2/ 2022-04-05T17:43:05+00:00 https://fore.bio/publication/duplicated-publication-34-2-5-2/ 2022-04-05T17:44:11+00:00